Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI 1703880 |
| Synonyms | |
| Therapy Description |
BI 1703880 acts as a STING agonist, potentially resulting in increased type 1 interferon response and cytokine release (Journal for ImmunoTherapy of Cancer 2022;10, Suppl_2, 626). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI 1703880 | BI-1703880|BI1703880 | STING1 Agonist 21 | BI 1703880 acts as a STING agonist, potentially resulting in increased type 1 interferon response and cytokine release (Journal for ImmunoTherapy of Cancer 2022;10, Suppl_2, 626). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|